Cancer Progress Conference to Present Cost-Benefit Considerations for Complex Therapeutics- Panelists Include Exacis Biotherapeutics CEO

Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will discuss strategies for optimal positioning of new therapies as a panel member at the Cancer Progress Conference. The panel, “Selling the Cell – Cost-Benefit Considerations for Complex Therapeutics,” will explore how best to balance the cost of developing new therapies with constraints on pricing. Dr. Fiore’s experience as CEO of multiple pharmaceutical and biotechnology companies and as acting CMO for several early-stage biotechnology companies, provides him with a deep understanding of the complex costs associated with development, manufacture, and delivery of sophisticated new therapeutics.

“As a healthcare community we recognize the significant costs associated with development of advanced therapeutics that hold promise to revolutionize the treatment of devastating diseases. At the same time, there are technologies and strategies we can employ to minimize the costs to the system without compromising therapeutic benefit.” said Dr. Fiore. “Lowering the costs associated with delivery of cell therapy treatments will be a major contributor to improving access to these lifesaving therapies.”

The panel will take place at 1 pm ET on Thursday, May 12.

Held May 10-12, 2022, the Cancer Progress Conference is the only oncology conference that facilitates discussions of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives. The conference will feature pivotal topics, frank discussions, vigorous debate, opportunities for audience questions and comments, and a partnering platform to enable meaningful connections and meetings with innovators, developers and investors.

Exacis is a development stage immuno-oncology company focused on harnessing the human immune system to cure cancer by engineering next generation off-the-shelf NK and T cell therapies aimed at hematologic malignancies and solid tumors. Exacis was founded in 2020 with an exclusive global license to a broad suite of patents covering the use of mRNA based cell reprogramming and gene editing technologies for use in generating engineered NK and T cells for oncology applications.

Exacis’ approach avoids the use of DNA and viruses and instead uses a proprietary mRNA based technology. Exacis uses the technology to generate iPSCs and to edit their genome to create stealthed, performance enhanced allogeneic NK and T cell products, termed ExaNK™, ExaCAR-NK™ and ExaCAR-T™ cells.

T and NK cells are types of human immune cells that are able to recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

Contact Exacis Biotherapeutics for further information and media: 

Exacis Biotherapeutics 

info@exacis.com